Improving CAR Treg therapy for Alzheimer's disease
Enhanced persistence of CAR Tregs in the CNS for Alzheimer’s disease therapy
['FUNDING_OTHER'] · DARTMOUTH COLLEGE · NIH-11017414
This study is looking at a new way to help treat Alzheimer's disease by using special immune cells that can reduce inflammation in the brain, and it aims to see if this approach can help slow down the disease for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DARTMOUTH COLLEGE (nih funded) |
| Locations | 1 site (HANOVER, UNITED STATES) |
| Trial ID | NIH-11017414 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of CAR T regulatory cells (Tregs) in treating Alzheimer's disease by improving their persistence in the central nervous system (CNS). The approach involves using genetically modified Tregs that can target and reduce inflammation associated with amyloid-beta accumulation, a key factor in Alzheimer's progression. By investigating the mechanisms of Treg function and their interaction with neuroinflammation, the research aims to develop a novel therapeutic strategy that could potentially slow down or halt disease progression. Patients may be involved in trials assessing the safety and efficacy of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those experiencing significant cognitive decline.
Not a fit: Patients with early-stage Alzheimer's or those without significant neuroinflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly slows the progression of Alzheimer's disease and improves cognitive function.
How similar studies have performed: Previous research has shown promise in using Tregs for neuroinflammatory conditions, suggesting potential success for this novel approach in Alzheimer's disease.
Where this research is happening
HANOVER, UNITED STATES
- DARTMOUTH COLLEGE — HANOVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SENTMAN, CHARLES L. — DARTMOUTH COLLEGE
- Study coordinator: SENTMAN, CHARLES L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer disease-specific antigen